1,823 individuals already recruited for PH real-world study on 'effectiveness' of COVID-19 vaccines
A total of 1,823 individuals have already been recruited to participate in the country’s yearlong real-world study on the effectiveness of coronavirus disease (COVID-19) vaccines, the Department of Science and Technology (DOST) said Friday, Nov. 5.

During his weekly report on Friday, DOST Secretary Fortunato “Boy” T. de la Peña said the recruitment of participants for the post-COVID 19 vaccination surveillance project continues.
Citing the report of the Philippine Council for Health Research and Development (PCHRD), he said as of Oct. 29, 1,823 Filipinos have been included in the list of participants for the study seeking to “estimate the effectiveness” of COVID-19 vaccines that were granted with emergency use authorization (EUA) by the Food and Drug Administration (FDA).
The 12-month nationwide surveillance program which started in July this year is led by Dr. Regina Berba of UP-Manila.
De la Peña said also involved in the study are the Philippine Society for Microbiology and Infectious Diseases, local government units (LGUs) and the Department of Health (DOH).
The immunosurveillance program is targeting at least 5,000 fully vaccinated adults via antibody testing that will be done at weeks 2, 12, 24, 36, and 52 after receiving the second dose, he said.
“The study is expected to determine the duration of protection of the EUA approved COVID 19 vaccines as well as the possible factors affecting vaccine effectiveness,” the DOST chief said.
The DOST bared last week that six more sites have been identified for the study entitled, “Philippine Vaccine Effectiveness Project: A Post-COVID-19 Vaccination Surveillance Among Filipino Adults.”
DOST Undersecretary for Research and Development (R&D) Dr. Rowena Cristina Guevara said aside from the University of the Philippines-Philippine General Hospital (UP-PGH), Baguio, Bacoor, Cebu, Davao, Philippine National Police (PNP), and San Miguel Corporation (SMC) have also been named as “study implementation sites.”
“Other study implementation sites that are almost ready to start once approved by the Research Ethics Boards are as follows: Baguio, Bacoor, Cebu, Davao, Philippine National Police (PNP), and San Miguel Corporation (SMC),” Guevara told the Manila Bulletin in a Viber message.
Guevara said interim data may be released to the Department of Health (DOH) and the general public by next month.
De la Peña announced late May that the Philippines will conduct a yearlong surveillance study to “determine the duration of protection of the EUA-approved COVID-19 vaccines as well as the possible factors affecting vaccine effectiveness.”
He said the project has been approved with a budget of P 114.9 million.
The FDA has so far issued EUA to COVID-19 vaccine developed by American drug firm Moderna, American drugmaker Pfizer, United Kingdom-based AstraZeneca, China’s Sinovac, Russia's Gamaleya Research Institute, India's Bharat Biotech, and US-based firm Johnson & Johnson.